WinstonWınston
Back
Stock

Eli Lilly and Company

LLY
83
Drug Manufacturers - General · Healthcare
Also trades as: LLY.DE EUR 1,123.40 (-0.88%) · LLY.SW CHF 955.00 (+0.00%)
Price
$1257.03
+5.42 (+0.43%)
Market Cap
$1.18T
Winston Score
83
Winston is happy
A high-quality business with solid fundamentals.
Data as of Oct 18, 2026 · filings through Jun 30, 2026

§How the score breaks down

Quality
Exceptional
30/30
Growth
Exceptional
20/20
Cash Flow
Exceptional
9/10
Stability
Strong
7/10
Valuation
Good
6/10
Ownership
Good
8/15
Dividends
Good
3/5

83 of 100 counted points = Winston Score 83.

Track this stock — start free trial

Share count falling — buybacks

−5.8% over 4y

The company has reduced its share count over this period, returning value to shareholders through buybacks.

Diluted shares outstanding: 953.7M (2021) → 898.0M (2025)

§Winston Score History

The full picture

Eli Lilly is a large pharmaceutical company that discovers, makes, and sells prescription medicines. Its biggest products right now are Mounjaro and Zepbound for diabetes and weight loss, plus Verzenio for breast cancer and Jardiance for diabetes. Doctors and hospitals are the main customers, and patients use these drugs to treat serious chronic conditions.

Lilly makes money by selling branded prescription drugs, mostly at high prices protected by patents. It operates globally, with a large share of revenue coming from the United States, and it is one of the largest drug companies in the world by market value. Its main competitive advantage is its patent-protected drug portfolio and a strong pipeline of new medicines in development. The biggest growth driver is demand for its GLP-1 weight-loss and diabetes drugs, which has been enormous, but the main risk is that patents eventually expire, opening the door to cheaper generic competition.

Politician Trades

43 trades / 12mo

23 Congressional buys and 20 sells on LLY in the last 12 months.

Unlock the full Smart Money Map — every trade plotted on the price chart with politicians, amounts and returns since each trade. Founder's Deal is $57/mo locked for life.

Unlock politician trades

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+47.7% YoY

YoY Growth Rate

Revenue accelerating

EPS Growth

+26.2% YoY

YoY Growth Rate

Strong earnings growth

R&D Spend

$13.3B/ year

↑ Rising (+21% vs prior year)

20.5% of revenue

In line with sector average (18%)

Investing heavily in future products and technology

Insider Activity

9.9%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

$12.8B cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Company generates more cash than it spends — no dilution risk from fundraising

Revenue accelerating

Eli Lilly and Company grew revenue 48% year-over-year and the growth rate is speeding up. That's the kind of momentum growth investors look for — the question is whether margins can follow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
85.8%
Premium pricing power — 85.8% gross margin
Profit after running costs
Operating Margin
39.1%
Excellent — 39.1% operating margin
Return on the money invested
ROCE
39.4%
Exceptional — 39.4% return on capital

ROIC above 25%. Every dollar invested in the business earns more than 25 cents back per year.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
+49.6%
Fast-growing sales (+49.6% YoY)
Profit growth
EPS YoY
+94.3%
Earnings growing fast (+94.3% YoY)

Earnings growing 25%+ a year. The compounder zone.

How steady the profit is
EPS Consistency
8/8 quarters
Every recent quarter grew earnings vs last year

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
105%
Turns 105% of profit into real cash
Spare cash per sale
FCF Margin
25.2%
Converts sales into free cash efficiently (25.2%)

Free cash flow margin above 20%. Out of every $100 in sales, more than $20 is real cash they keep.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
1.62
Elevated debt (1.62)
Covers its interest
Interest Cover
35.72x
Comfortably covers interest (35.7x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
42.1x
Pricey — P/E 42.1

P/E over 35. The market is pricing in heavy, sustained growth.

Cheaper or dearer next year
P/E vs Forward
+20.1
GROWING
Earnings expected to grow meaningfully — cheaper on forward P/E (42.1 → 22.0)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend
Dividend Yield
0.58%
Small dividend — 0.58% yield

Modest yield. The bulk of any return needs to come from price appreciation.

Dividend record
Dividend Growth
+15.3%
Dividend growing fast (15.3% YoY)
Payout Ratio
22%
no trend
Pays out a modest share of profit and keeps the rest to reinvest. Room to keep paying through a weak year.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial